Insmed Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Insmed de 39.2% y 34.4% por año respectivamente. Se prevé que el BPA crezca en un 41.6% al año. Se espera que la rentabilidad financiera sea de -44.2% en 3 años.

Información clave

44.9%

Tasa de crecimiento de los beneficios

46.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	25.0%
Tasa de crecimiento de los ingresos	35.2%
Rentabilidad financiera futura	-487.0%
Cobertura de analistas	Good
Última actualización	13 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

Recent updates

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Sep 20

Insmed rises 16% on better-than-expected Q2 result

Aug 04

Is Insmed (NASDAQ:INSM) A Risky Investment?

Jun 24

Insmed: Temporarily Stuck

Feb 19

Is Insmed (NASDAQ:INSM) Using Debt Sensibly?

Dec 11

Is Insmed (NASDAQ:INSM) Using Too Much Debt?

Sep 10

Estimating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Jun 10

Insmed to raise $250M in stock offering, $500M in notes offering

May 10

We Think The Compensation For Insmed Incorporated's (NASDAQ:INSM) CEO Looks About Right

May 06

Is Insmed (NASDAQ:INSM) Weighed On By Its Debt Load?

Apr 06

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:INSM - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	837	-408	-273	-243	13
12/31/2025	517	-652	-585	-543	15
12/31/2024	354	-708	-643	-615	15
3/31/2024	315	-747	-589	-574	N/A
12/31/2023	305	-750	-550	-536	N/A
9/30/2023	281	-724	-524	-509	N/A
6/30/2023	269	-696	-476	-462	N/A
3/31/2023	257	-547	-453	-442	N/A
12/31/2022	245	-482	-410	-400	N/A
9/30/2022	242	-434	-388	-381	N/A
6/30/2022	221	-416	-374	-367	N/A
3/31/2022	201	-438	-348	-340	N/A
12/31/2021	188	-435	-371	-363	N/A
9/30/2021	174	-424	-354	-346	N/A
6/30/2021	171	-375	-336	-329	N/A
3/31/2021	168	-319	-295	-290	N/A
12/31/2020	164	-294	-226	-219	N/A
9/30/2020	169	-245	-215	-197	N/A
6/30/2020	164	-242	-223	-191	N/A
3/31/2020	151	-247	-276	-235	N/A
12/31/2019	136	-254	-293	-251	N/A
9/30/2019	101	-293	-310	-276	N/A
6/30/2019	62	-320	-311	-290	N/A
3/31/2019	32	-330	-278	-264	N/A
12/31/2018	10	-324	-273	-258	N/A
9/30/2018	N/A	-298	-248	-236	N/A
6/30/2018	N/A	-256	-219	-209	N/A
3/31/2018	N/A	-224	-198	-190	N/A
12/31/2017	N/A	-193	N/A	-160	N/A
9/30/2017	N/A	-196	N/A	-169	N/A
6/30/2017	N/A	-188	N/A	-162	N/A
3/31/2017	N/A	-180	N/A	-154	N/A
12/31/2016	N/A	-176	N/A	-147	N/A
9/30/2016	N/A	-139	N/A	-116	N/A
6/30/2016	N/A	-132	N/A	-109	N/A
3/31/2016	N/A	-124	N/A	-105	N/A
12/31/2015	N/A	-118	N/A	-101	N/A
9/30/2015	N/A	-105	N/A	-86	N/A
6/30/2015	N/A	-98	N/A	-83	N/A
3/31/2015	N/A	-92	N/A	-77	N/A
12/31/2014	N/A	-79	N/A	-64	N/A
9/30/2014	N/A	-78	N/A	-66	N/A
6/30/2014	N/A	-71	N/A	-61	N/A
3/31/2014	N/A	-57	N/A	-48	N/A
12/31/2013	N/A	-56	N/A	-47	N/A
9/30/2013	N/A	-55	N/A	-42	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que INSM siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que INSM siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que INSM siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (34.4% al año) de INSM crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (34.4% al año) de INSM crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: INSM se prevé que no sea rentable en 3 años.

Insmed Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Consensus EPS estimates fall by 14%, revenue upgraded

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Recent updates

New major risk - Financial position

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

President exercised options to buy US$1.4m worth of stock.

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Full year 2023 earnings: EPS misses analyst expectations

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Chief Medical Officer notifies of intention to sell stock

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

President notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Consensus EPS estimates fall by 14%, revenue upgraded

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Chief Commercial Officer recently sold US$64k worth of stock

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold US$68k worth of stock

President exercised options to buy US$4.3m worth of stock.

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Chief Financial Officer notifies of intention to sell stock

President recently sold US$139k worth of stock

Insufficient new directors

Independent Director recently bought US$796k worth of stock

Insmed Incorporated Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated announced that it expects to receive $625 million in funding

Insmed inks financing agreements to raise $500M

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Insmed Incorporated to Report Q3, 2022 Results on Oct 27, 2022

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

President exercised options and sold US$5.1m worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insmed Incorporated Reiterates Revenue Guidance for the Full Year 2022

Insmed rises 16% on better-than-expected Q2 result

Insmed Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Senior VP & General Counsel recently sold US$22k worth of stock

President exercised options and sold US$661k worth of stock

Is Insmed (NASDAQ:INSM) A Risky Investment?

Insmed Incorporated Names Drayton Wise as Chief Commercial Officer

Independent Director recently bought US$344k worth of stock

First quarter 2022 earnings: EPS exceeds analyst expectations

Insmed Incorporated to Report Q1, 2022 Results on May 05, 2022

Insmed Incorporated, Annual General Meeting, May 11, 2022

Insmed: Temporarily Stuck

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Insmed Incorporated Provides Earnings Guidance for the Full Year 2022

Insmed Incorporated to Report Q4, 2021 Results on Feb 17, 2022

President recently sold US$72k worth of stock

Is Insmed (NASDAQ:INSM) Using Debt Sensibly?

Chief People Strategy Officer exercised options and sold US$1.1m worth of stock

Independent Director recently bought US$429k worth of stock

Third quarter 2021 earnings released: US$0.96 loss per share (vs US$0.63 loss in 3Q 2020)

President exercised options and sold US$2.3m worth of stock

Chief Compliance Officer exercised options and sold US$248k worth of stock